Methods

Exclusion criteria
Women were excluded if they had respiratory failure, heart failure grade III-IV NYHA, unstable cardiovascular or psychiatric disorders, pregnancy, severe daytime sleepiness (Epworth sleepiness score [ESS]>18), prior diagnosis of OSA or CPAP treatment, restless legs or narcolepsy, or central sleep apnoea (more than 50% of apnoeic events were central).
Sleep Study
Every sleep study was manually scored by skilled staff. All the studies included continuous recording of the oro-nasal flow and pressure, respiratory movements, and oxyhaemoglobin saturation (SaO2). Apnoea was defined as complete cessation of oro-nasal flow for ≥10 seconds and was classified as either obstructive or central, based on the presence or absence of respiratory efforts. Hypopnoea was defined as a 30-90% reduction in oro-nasal flow for ≥10 seconds followed by a ≥3% decrease in SaO2. The AHI was defined as the number of apnoeas plus hypopnoea per hour of recording. A sleep study was considered as valid if at least 4 hours of recording and more than 3 hours of subjective sleep were reported. Invalid studies were repeated.
Baseline visit and final visit
The baseline visit took place after OSA diagnosis. In this visit, the participants completed a standardized protocol, office BP was measured, blood samples were collected, and women were randomized to either CPAP or conservative treatment.
Those women allocated to CPAP therapy underwent the CPAP titration on the same or next night, and fixed CPAP was begun the day after titration.
The final visit was scheduled after 12 weeks of the CPAP onset in the treatment group, and after 12 weeks of randomization in the conservative treatment (control) group.
Randomization and Intervention
The optimal pressure was determined in a centralized manner, by two blinded expert researchers, based on the visual evaluation of the raw data recording from the night study, with no significant leaks (less than 0.40 L/s). This fixed pressure was maintained throughout the study.
Statistical analysis
Normality in the variables distribution was assessed with the Kolmogorov test.
Baseline continuous variables were compared using Student t-test or MannWhitney test, and categorical variables were compared using Chi-square or Fisher exact tests.
An additional per-protocol analysis was conducted, including in the CPAP group only those patients who used the device for at least 4 hours/night on average.
Missing values for the primary endpoint were imputed by baseline observation carried forward.
We conducted sensitivity analyses to investigate the effect of CPAP therapy on BP measurements in specific subgroups of women of clinical interest, such as those with severe OSA (AHI≥30), daytime sleepiness (ESS>10), and high BP values at entry (SBP≥140 mmHg or DBP≥90 mmHg).
The statistical analyses were performed using a blind evaluation of the study groups.
Results
The average effective CPAP pressure was 10.3 (2.3) cmH2O. In the 151 women allocated to the CPAP group, the mean nightly use of the device was 4.8 (2.5) hours/night, with 113 (75.3%) participants showing adherence for at least 4 hours/night. 
